PSNI assessing if any offences linked to recall of 3,000 neurology patients – The Irish Times

Posted on by

The PSNI has confirmed it is assessing whether any criminal offences have been identified following the recall of more than 3,000 neurology patients in Northern Ireland.

The recall happened last year after an independent review of work carried out by consultant neurologist Dr Michael Watt, who has been suspended from practising medicine.

Recent BBC Spotlight programmes reported that one-in-five of the patients who were re-examined were found to have been misdiagnosed by the neurologist.

Dr Watt, who worked at the Royal Victoria Hospital in Belfast, dealt with conditions such as epilepsy, Parkinsons Disease and multiple sclerosis. A report into the cases that was due to be published in June of last year by the Norths Department of Health. However, it never was.

Spotlight reported that it had obtained details of the report and that it indicated that out of almost 3,000 patients, about 2,000 were said to have received a secure diagnosis. More than 600 were given insecure diagnoses, while another 329 diagnoses were uncertain, the BBC programme reported.

The PSNI on Wednesday said it was investigating the matter.

We are aware of the recall of neurology patients by the Belfast Health and Social Care Trust and have met with senior officials within the Department of Health to discuss the issue, a PSNI spokeswoman said.

The department has agreed to provide us with further information so that we can assess how best to move forward and to enable us to determine if any potential criminal offences can be identified.

SDLP deputy leader Nichola Mallon, who has campaigned on behalf of Dr Watts patients, said she had seen at first hand the emotional and mental impact of the ordeal on the patients.

There are serious questions for the Belfast Trust and Department of Health about how theyve handled this situation, she said. These patients were also promised openness and transparency and yet they are continually met with a wall of silence...They feel abandoned and ignored. They deserve better.

See the article here:
PSNI assessing if any offences linked to recall of 3,000 neurology patients - The Irish Times

Global Neurovascular or Interventional Neurology Devices Market 2019 by Manufacturers, Regions, Type and Application, Forecast to 2025 – Industry News…

Posted on by

The "Neurovascular or Interventional Neurology Devices Market" report contains a wide-extending factual assessment for Neurovascular or Interventional Neurology Devices, which enables the customer to separate the future complicity and estimate the right execution. The advancement rate is evaluated dependent on insightful examination that gives credible information on the worldwide Neurovascular or Interventional Neurology Devices market. Imperatives and advancement points are merged together after a significant comprehension of the improvement of the Neurovascular or Interventional Neurology Devices market. The report is all around made by considering its essential information in the overall Neurovascular or Interventional Neurology Devices market, the essential components in charge of the interest for its products and administrations. Our best analysts have surveyed the Neurovascular or Interventional Neurology Devices market report with the reference of inventories and data given by the key players (Stryker, Medtronic, Johnson and Johnson, Terumo, Penumbra, Boston Scientific, Abbott Laboratories, Merit Medical Systems, Microport Scientific), flexible sources and records that help to upgrade cognizance of the related methodological conditions.

Ask for sample link here: https://www.intenseresearch.com/market-analysis/global-neurovascular-or-interventional-neurology-devices-market-2019.html#request-sample

The Neurovascular or Interventional Neurology Devices market report shows a point by point division (Cerebral Thrombectomy Devices, Carotid Artery Stenting (CAS) System, Cerebral Aneurysm and AVM Endovascular Embolization Systems, Intracranial Stent Systems, Flow Diverter for Aneurysm) of the overall market reliant on development, product type, application, and distinctive techniques and systems. The point-to-point elucidation of the Neurovascular or Interventional Neurology Devices market's assembling system, the usage of advancement, conclusions of the world market players, dealers and shippers' order, and the explicit business data and their improvement plans would help our customers for future courses of action and movement planned to make due in the Neurovascular or Interventional Neurology Devices market.

The Neurovascular or Interventional Neurology Devices market report includes the latest mechanical enhancements and new releases to engage our customers to the configuration, settle on taught business decisions, and complete their required executions in the future. The Neurovascular or Interventional Neurology Devices market report moreover focuses more on current business and present-day headways, future methodology changes, and open entryways for the Neurovascular or Interventional Neurology Devices market. Nearby progression frameworks and projections are one of the key segments that clear up overall execution and incorporate key geological analysis (Hospital, Clinic).

Inquire about the report here: https://www.intenseresearch.com/market-analysis/global-neurovascular-or-interventional-neurology-devices-market-2019.html#inquiry-for-buying

The overall Neurovascular or Interventional Neurology Devices market is made with the fundamental and direct conclusion to exploit the Neurovascular or Interventional Neurology Devices market and participate in business progression for imperative business openings. The correct figures and the graphical depiction of the Neurovascular or Interventional Neurology Devices market are shown in a represented strategy. The report shows an examination of conceivable contention, current market designs and other basic characteristics all around the world.

Thanks for reading this article; you'll be able to additionally get individual chapter wise section or region wise report versions like North America, Europe, Asia-Pacific, South America, geographic area and continent.

Sorry! The Author has not filled his profile.

See the article here:
Global Neurovascular or Interventional Neurology Devices Market 2019 by Manufacturers, Regions, Type and Application, Forecast to 2025 - Industry News...

Books | UH Neurological Institute | University Hospitals …

Posted on by

Brain Tumor and Neuro Oncology

Surgery of the Cerebellopontine Angle

By: Nicholas C. Bambakidis, Cliff A. Megerian, Robert F. Spetzler

Textbook of Epilepsy Surgery

Edited by: Hans O. Lders, MD, PhD

The Myth of Alzheimers

By: Peter J. Whitehouse, M.D., Ph.D. with Daniel George, M.Sc.

What you arent being told about todays most dreaded diagnosis.

Treating Dementia: Do We Have a Pill for It?

By: Jesse F. Ballenger PhD (Editor), Peter J. Whitehouse MD PhD (Editor), Constantine G. Lyketsos MD MHS (Editor), Peter V. Rabins MD MPH (Editor), Jason H. T. Karlawish MD (Editor)

Special feature on how culture, language and values affect drug marketing for dementia treatment options around the world.

Electromyography in Clinical Practice: A Case Study Approach

By: Bashar Katirji, M.D.

In its second edition, this textbook is used in training programs across the country.

Electromyography and Neuromuscular Disorders: Clinical-Electrophysiologic Correlations

By: David C. Preston, M.D. and Barbara E. Shapiro, M.D., Ph.D.

In its second edition, this textbook with CD-ROM is recognized among the best textbooks for students, residents and practitioners.

Neuromuscular Disorders in Clinical Practice

Editors: Bashar Katirji, MD, Henry J. Kaminski, MD, David C. Preston, MD, Robert L. Ruff, MD, Barbara E. Shapiro, MD, PhD

The most comprehensive and authoritative textbook in the field with chapters contributed by the Neuromuscular Center staff.

Diagnostic Criteria in Neurology

By: Alan J. Lerner, M.D.

Encyclopedia of the Neurological Sciences

By: Michael J. Aminoff, M.D., DSc, FRCP and Robert B. Daroff, M.D.

Neurology in Clinical Practice

By: Walter G. Bradley, D.M., FRCP, Robert B. Daroff, M.D., Gerald Fenichel, M.D., Joseph Jankovic, M.D.

In its fifth edition, this book addresses the most current clinical neurology and leads you through the thought processes of seasoned clinicians.

The Little Black Book of Neurology

By: Alan J. Lerner, M.D.

Neuroimaging in Neurology

By: David C. Preston and Barbara E. Shapiro

The Neurology of Eye Movements, Fourth Edition

By: R. John Leigh and David S. Zee

Struck by the Hand of God

The Collision of Stroke and World History

By: Michael DeGeorgia, M.D.

What if the strokes of Woodrow Wilson, FDR, Winston Churchill, and other world leaders had been treated today? Perhaps the pen of history would have written a different story.

Continued here:
Books | UH Neurological Institute | University Hospitals ...

Physical activity, common brain pathologies … – n.neurology.org

Posted on by

Aron S. Buchman

From the Rush Alzheimer's Disease Center (A.S.B., L.Y., R.S.W., R.J.D., C.G., S.E.L., J.A.S., D.A.B.), and Departments of Neurological Sciences (A.S.B., L.Y., R.S.W., C.G., S.E.L., J.A.S., D.A.B.), Radiology (R.J.D.), Psychology (R.S.W.), and Pathology (Neuropathology) (J.A.S.), Rush University Medical Center, Chicago, IL; and Department of Neurology (A.L.), University of Toronto, Canada.

Lei Yu

From the Rush Alzheimer's Disease Center (A.S.B., L.Y., R.S.W., R.J.D., C.G., S.E.L., J.A.S., D.A.B.), and Departments of Neurological Sciences (A.S.B., L.Y., R.S.W., C.G., S.E.L., J.A.S., D.A.B.), Radiology (R.J.D.), Psychology (R.S.W.), and Pathology (Neuropathology) (J.A.S.), Rush University Medical Center, Chicago, IL; and Department of Neurology (A.L.), University of Toronto, Canada.

Robert S. Wilson

From the Rush Alzheimer's Disease Center (A.S.B., L.Y., R.S.W., R.J.D., C.G., S.E.L., J.A.S., D.A.B.), and Departments of Neurological Sciences (A.S.B., L.Y., R.S.W., C.G., S.E.L., J.A.S., D.A.B.), Radiology (R.J.D.), Psychology (R.S.W.), and Pathology (Neuropathology) (J.A.S.), Rush University Medical Center, Chicago, IL; and Department of Neurology (A.L.), University of Toronto, Canada.

Andrew Lim

From the Rush Alzheimer's Disease Center (A.S.B., L.Y., R.S.W., R.J.D., C.G., S.E.L., J.A.S., D.A.B.), and Departments of Neurological Sciences (A.S.B., L.Y., R.S.W., C.G., S.E.L., J.A.S., D.A.B.), Radiology (R.J.D.), Psychology (R.S.W.), and Pathology (Neuropathology) (J.A.S.), Rush University Medical Center, Chicago, IL; and Department of Neurology (A.L.), University of Toronto, Canada.

Robert J. Dawe

From the Rush Alzheimer's Disease Center (A.S.B., L.Y., R.S.W., R.J.D., C.G., S.E.L., J.A.S., D.A.B.), and Departments of Neurological Sciences (A.S.B., L.Y., R.S.W., C.G., S.E.L., J.A.S., D.A.B.), Radiology (R.J.D.), Psychology (R.S.W.), and Pathology (Neuropathology) (J.A.S.), Rush University Medical Center, Chicago, IL; and Department of Neurology (A.L.), University of Toronto, Canada.

Chris Gaiteri

From the Rush Alzheimer's Disease Center (A.S.B., L.Y., R.S.W., R.J.D., C.G., S.E.L., J.A.S., D.A.B.), and Departments of Neurological Sciences (A.S.B., L.Y., R.S.W., C.G., S.E.L., J.A.S., D.A.B.), Radiology (R.J.D.), Psychology (R.S.W.), and Pathology (Neuropathology) (J.A.S.), Rush University Medical Center, Chicago, IL; and Department of Neurology (A.L.), University of Toronto, Canada.

Sue E. Leurgans

From the Rush Alzheimer's Disease Center (A.S.B., L.Y., R.S.W., R.J.D., C.G., S.E.L., J.A.S., D.A.B.), and Departments of Neurological Sciences (A.S.B., L.Y., R.S.W., C.G., S.E.L., J.A.S., D.A.B.), Radiology (R.J.D.), Psychology (R.S.W.), and Pathology (Neuropathology) (J.A.S.), Rush University Medical Center, Chicago, IL; and Department of Neurology (A.L.), University of Toronto, Canada.

Julie A. Schneider

From the Rush Alzheimer's Disease Center (A.S.B., L.Y., R.S.W., R.J.D., C.G., S.E.L., J.A.S., D.A.B.), and Departments of Neurological Sciences (A.S.B., L.Y., R.S.W., C.G., S.E.L., J.A.S., D.A.B.), Radiology (R.J.D.), Psychology (R.S.W.), and Pathology (Neuropathology) (J.A.S.), Rush University Medical Center, Chicago, IL; and Department of Neurology (A.L.), University of Toronto, Canada.

David A. Bennett

From the Rush Alzheimer's Disease Center (A.S.B., L.Y., R.S.W., R.J.D., C.G., S.E.L., J.A.S., D.A.B.), and Departments of Neurological Sciences (A.S.B., L.Y., R.S.W., C.G., S.E.L., J.A.S., D.A.B.), Radiology (R.J.D.), Psychology (R.S.W.), and Pathology (Neuropathology) (J.A.S.), Rush University Medical Center, Chicago, IL; and Department of Neurology (A.L.), University of Toronto, Canada.

Read more:
Physical activity, common brain pathologies ... - n.neurology.org

Europe Pacemakers Market to 2027 – Regional Analysis and Forecasts By Product Type, Technology, End User, and Country – ResearchAndMarkets.com -…

Posted on by

DUBLIN--(BUSINESS WIRE)--The "Europe Pacemakers Market to 2027 - Regional Analysis and Forecasts By Product Type By Technology, By End User, and Country" report has been added to ResearchAndMarkets.com's offering.

The Europe pacemaker market is expected to reach US$ 2,408.5 Mn in 2027 from US$ 1,248.7 Mn in 2018. The market is projected to grow with a CAGR of 7.7% from 2019-2027.

Electronic implants are playing a pioneering role that helps to detect specific medical parameters. Additionally, these implants are able to take immediately autonomous therapeutic measures, combining diagnosis and treatment in a single system. The electronic medical implant is an emerging field in the medical industry and has led to various developments of the products, in the field of cardiology, neurology, and otology. Many of the market players are developing novel products in order to minimize the burden of cardiovascular diseases, neurological disorders, and hearing disorders.

For instance, in November 2017, Medtronic launched Azure pacemakers with BlueSync technology that increases the life of the pacemakers, thus reducing the number of device replacements. It also enables to secure and automatic wireless data transmission to physicians. Similarly, in July 2016, BIOTRONIK headquartered in Germany received CE approval for its new Edora pacemakers and cardiac resynchronization therapy pacemakers (CRT-Ps).

Moreover, the presence of pacemaker manufacturers in the European region is also likely to influence the pacemaker market in the European region. Osypka Medical GmbH, Cardiac Impulse S.R.L., Sorin Biomedica C.R.M., S.R.L. are manufacturers located in Europe.

In 2018, Europe pacemaker market held a market share of 22.8% of the global pacemaker market. The implantable pacemakers segment expected to dominate its market share and was valued at US$ 855.5 Mn in 2018 and is anticipated to reach US$ 1,687.2 Mn by 2027. On the other hand, implantable pacemakers segment is also anticipated to witness the fastest growth rate of 8.0% during the forecast period, 2019 to 2027.

Similarly, in 2018 single-chambered pacemaker segment by technology was valued at US$ 890.2 Mn in 2018 and is anticipated to reach US$ 1,736.8 Mn by 2027 and is also expected to grow at the fastest growth rate of 7.9% during the forecast period.

Furthermore, the hospitals & clinics segment held the largest market share of is also anticipated to witness the fastest growth rate of 8.0% during the forecast period, 2019 to 2027. This segment is also expected to dominate the market in 2027 as it is the primary care center for most of the population.

Key Topics Covered:

1. Introduction

1.1 Scope Of The Study

1.2 Research Report Guidance

2. Europe Pacemakers Market - Key Takeaways

3. Europe Pacemakers Market - Market Landscape

3.1 Overview

3.2 Market Segmentation

3.3 Pest Analysis

4. Europe Pacemakers Market- Key Market Dynamics

4.1 Key Market Drivers

4.1.1 Increasing Number Of New Cases of Cardiovascular Diseases (CVD) in Europe

4.1.2 Rapid Technological Advancements in Europe

4.2 Key Market Restraints

4.2.1 Faulty Pacemaker Raises Concerns Over Implantation

4.3 Key Market Opportunities

4.3.1 Growing Medical Technology Industry The European Region

4.4 Future Trends

4.4.1 The Leadless Pacemaker is a New Era In Cardiac Pacing

4.5 Impact analysis

5. Pacemakers Market - Europe Analysis

5.1 Europe Pacemakers Market Revenue Forecasts And Analysis

5.2 Market Positioning

5.3 Performance Of Key Players

6. Pacemakers Market - Europe Regulatory Scenario

7. Europe Pacemakers Market Analysis - By Product Type

7.1 Overview

7.2 Europe Pacemakers Market, By Product Type, 2018 & 2027 (%)

7.3 Europe Pacemakers Market Revenue And Forecasts To 2027, By Product Type (Us$ Mn)

7.4 Implantable Pacemakers Market

7.5 External Pacemakers Market

8. Europe Pacemakers Market Analysis - By Technology

8.1 Overview

8.2 Europe Pacemakers Market, By Technology, 2018 & 2027 (%)

8.3 Europe Pacemakers Market Revenue And Forecasts To 2027, By Technology (Us$ Mn)

8.4 Single Chambered Market

8.5 Dual Chambered Market

8.6 Bi-Ventricular Market

9. Europe Pacemakers Market Analysis - By End User

9.1 Overview

9.2 Europe Pacemakers Market, By End User, 2018 & 2027 (%)

9.3 Europe Pacemakers Market Revenue And Forecasts To 2027, By End User (Us$ Mn)

9.4 Hospitals Market

9.5 Ambulatory Surgical Centres Market

9.6 Others Market

10. Europe Pacemakers market

11. Pacemakers Market - Industry Landscape

11.1 Overview

11.2 Comparative Company Analysis

11.3 Growth Strategies Done By The Companies In The Market, (%)

11.4 Organic Developments

11.5 Inorganic Developments

12. Pacemakers Market-Key Company Profiles

For more information about this report visit https://www.researchandmarkets.com/r/gwns81

See the original post here:
Europe Pacemakers Market to 2027 - Regional Analysis and Forecasts By Product Type, Technology, End User, and Country - ResearchAndMarkets.com -...

Letter from the Director | UH Neurological Institute …

Posted on by

Nicholas C. Bambakidis,MD, FAHA, FAANS

University Hospitals Neurological Institute combines a comprehensive team of neurology and neurosurgery specialists throughout the Northeast Ohio. Our providers are world-class experts who are readily available to care for patients with any number of neurological disorders, offering treatment for the entire spectrum of both medical and surgical diseases of the brain and spine. These include diagnosis such as stroke and cerebrovascular disease, brain and spinal tumors and cancer, headache, movement disorders such as Parkinsons Disease, and many other complex neurological problems.

The specialists within UH Neurological Institute are also part of a multidisciplinary team within the University Hospitals Spine Institute that treat patients with all manner of spinal disorders and pain syndromes. Our physicians perform nationally recognized research throughout this disease spectrum as well, and this means that patients often have access to the latest clinical trials and research protocols.

Our specialists and patient-centric approach to care is unrivaled not just in Northeast Ohio but nationally and internationally as well. As director of UH Neurological Institute, I am proud of our efforts in bringing this care to those who entrust their care to us.

Sincerely,

Nicholas C. Bambakidis, MD, FAHA, FAANSDirector and Vice President, University Hospitals Neurological InstituteProfessor of Neurological Surgery, Case Western Reserve University School of Medicine

View post:
Letter from the Director | UH Neurological Institute ...

Neurology – Overview – Mayo Clinic

Posted on by

Diagnosing and treating more than 500 neurological conditions

Mayo Clinic's top-ranked team of neurologists diagnoses and treats more than 500 neurological conditions, including many rare or complex disorders.

The Mayo Clinic Department of Neurology is one of the largest in the world. It includes more than 100 subspecialized experts trained in epilepsy, movement disorders, dementias and other cognitive conditions, stroke and cerebrovascular diseases, neuro-oncology, multiple sclerosis and demyelinating disorders, autoimmune neurology, pediatric neurology, neurophysiology, headache, neuromuscular diseases, peripheral nerve, sleep neurology, and speech pathology. These care providers work together to evaluate and treat people utilizing the most advanced techniques and technologies.

Neurological services are also provided to children at Mayo Clinic in Rochester, Minnesota. Neurologists trained in treating children work in collaboration with doctors trained in treating children and adolescents as well as other pediatric specialists.

Many Mayo Clinic Health System facilities also provide neurological care. Neurologists at Mayo Clinic's campus in Minnesota also provide care for people at several regional clinics and hospitals each week. A primary care provider at the location refers individuals for appointments with the visiting neurologist.

Mayo Clinic Health System clinics, hospitals and health care facilities serve more than 60 communities in Iowa, Wisconsin and Minnesota. These sites provide Mayo Clinic neurology and neurosurgery care to their local communities.

April 11, 2018

Follow this link:
Neurology - Overview - Mayo Clinic

NC State Veterinary Hospital Neurology Service | NC State …

Posted on by

Appointment GuidelinesWe accept new cases only if they are referrals from a veterinarian. This ensures that the patient is initially referred to the most appropriate service within the Veterinary Hospital. Some cases, particularly orthopedic or cardiac cases, can show very similar signs to neurologic cases. This policy is also important because once discharged from the hospital, we will need to work with the patients veterinarian in order to provide continued, high quality care.

Appointment Hours

Emergency ServicesThere is always a board-certified neurologist on call to provide expert consultation and, where indicated, evaluation of emergency cases that present through the Veterinary Hospital emergency service.

How Do I Get An Appointment?Our service works on a referral only basis, so the primary veterinarian must first evaluate the patient and then contact our service directly to initiate the referral, if needed. The final arrangements for the date and time of the appointment are usually made directly with the client. If you do not have a referral, ask your primary veterinarian to give you one in order to make an appointment. We prefer to have the owner bring the patient to the neurology appointment rather than delegate this to a friend or relative, as it is often crucial to the management and outcome of the case that an accurate history be obtained. In many cases, this will involve information that only the owner is aware of.

What will happen during an appointment?

For the first appointment at the Veterinary Hospital, please allow 2-3 hours. The visit will start at the admission desk where a medical record is set up for the patient.

The client and patient will be met by either a student, clinical technician or veterinarian who will then take the patients history information. An initial review of any radiographs, bloodwork or other referral information from the primary veterinarian is also done at this time. It is the owners responsibility to ensure that this information is conveyed to the Veterinary Hospital in time for the appointment as the primary veterinarian may not be aware of the exact date of the appointment.

A physical examination will then be performed on the patient, followed by a neurologic examination. These may be performed initially by a student, intern or visiting resident. Following this, a neurology clinician (either a neurology resident or senior neurologist) will speak with the client to review the examination findings and to make recommendations on any other specific tests that are recommended to make a precise diagnosis. Depending upon the diagnostics needed and the treatment plan prescribed, the patient may need to be hospitalized for several days.

Frequently-Asked Questions

When will the diagnostic tests be performed?It is very important to realize that the major diagnostic tests are often run one or two days after the patient is brought to the Veterinary Hospital. This is done in order to refine exactly which tests will be required and to determine whether the patient can be safely anesthetized.

Can a diagnosis be given via a telephone consult?Unfortunately, it is usually impossible to determine a specific diagnosis from a telephone description provided by the client or from the referring veterinarian. In nearly all cases, a full patient history, thorough physical and neurologic examinations, and a series of tests are needed before we can provide a diagnosis for the patients condition.

What is a neurology specialist?

Specialists in veterinary neurology are certified by the ACVIM parent organization. Specialists (sometimes also known as Diplomates) have to meet strict training requirements as outlined below. In order to become a Neurology specialist, a veterinarian must:

Complete a one-year internship or equivalent training.Complete a residency training program (two or three year depending on the institution). In some schools, such as at NC State University, the residency training includes both medical neurology and neurosurgery.Fulfill the prescribed credentials requirements.Pass both the general Internal Medicine examination and the Neurology certifying examination.

Why might I need a neurology specialist?If your pet has a neurological problem of any sort, we would strongly recommend that you seek the advice of a board-certified neurologist. Under the term ACVIM Neurology board certification, a veterinary neurologist is considered to be an expert in neurology, which can include both medical neurology and neurosurgery. Some neurologists have more training in neurosurgery than others, and some neurologists choose not to do neurosurgery. The four neurologists at the Veterinary Hospital are all trained in neurosurgery as well as medical neurology.

Here is the original post:
NC State Veterinary Hospital Neurology Service | NC State ...

The Neurology Center – Houston, Texas Neurologists | Privia

Posted on by

The Neurology Center - Houston, Texas Neurologists | Privia Skip to content

The Neurology Center can attribute their success to their highly skilled team of dedicated neurologists who work hard for our patients prolonged treatment and care.

Our goal at The Neurology Center is to ensure that all of our patients receive quality care and expert treatment. Well work with you to ensure you live a full, healthy life.

FINALLY,

A CONVENIENT DOCTORS APPOINTMENTTHAT WORKS FOR YOU.

MAKE YOUR NEXT APPOINTMENT A VIRTUAL VISIT

Dear Patients: We are moving! Beginning February 16, 2017, The Neurology Center will be in our new location at the Houston Medical Center Plaza, 6655 Travis St., Suite 600, Houston, Read More

As of August 9, 2016, we are proud members of Privia Medical Group!

The Neurology Center is a proud member of Privia Medical Group. The best doctors in our community have joined together to form Privia Medical Group (PMG), a multi-specialty, high-performance medical group that puts patients first. Our physicians are united by the mission of providing better, more coordinated care for their patients.

To learn more about Privia Medical Group and find other Privia doctors, please visit our website.

6655 Travis Street Suite 600

Privia Medical Group offers patients personalized and secure 24/7 online access to their health records, as well as the ability to communicate with your medical care team through our patient portal.

The easiest way to book an appointment with your provider.

Review prescription medications and request prescription renewals.

Send and receive secure messages with your medical care team.

Quick access to your secure electronic medical record and test results.

Pay your invoices by credit card, securely and conveniently.

Read more:
The Neurology Center - Houston, Texas Neurologists | Privia

Nearly 80 Percent of Americans Don’t Have Timely Access to… : Neurology Today – LWW Journals

Posted on by

Article In Brief

Stroke specialists discuss strategies to make endovascular thrombectomy (EVT) more accessible to many patients who don't have access to the therapy.

Fewer than one-fifth of Americans have ready access to hospitals that offer endovascular thrombectomy (EVT), and in some parts of the country the availability of the clot-busting procedure is even more scant.

Approximately 61 million (19.8 percent) of Americans have direct EVT-access within 15 minutes, while 95 million (30.9 percent ) Americans are within 30 minutes of a center that offers the procedure, the study reported in the February 19 online edition of Stroke.

In addition to analyzing the availability of EVT around the US, the study also considered whether it would be more beneficial to add more EVT programs or to implement policies that allow emergency medical crews to bypass closer non-EVT centers to get to a center with EVTeven if that takes more time.

Bypassing [closer non-EVT centers] showed more potential for maximizing direct EVT access, the study concluded. National and state efforts should focus on identifying gaps and tailoring solutions to improve EVT access.

James C. Grotta, MD, FAAN, a study coauthor and director of stroke research and director of the Mobile Stroke Unit at Memorial Hermann Hospital in Houston, said EVT is not unlike some other new therapies and technologies that took off without much thought to the issue of access.

We have this treatment (EVT) that is relatively new and very effective and requires specialized teams to carry it out, so now there is a tremendous amount of interest in reorganizing systems of care to improve the number of patients who can get treated, Dr. Grotta told Neurology Today.

The study authors noted that EVT improves clinical outcomes, reduces disability and saves lives for patients with acute ischemic stroke (AIS) due to anterior circulation large vessel occlusion (LVO).

Several clinical trials showed that EVT is effective if done within six hours of the last known point of wellness, though two recent trials known as DAWN and DEFUSE 3, have shown that EVT is efficacious and safe up to 24 hours in selected patients.

Current stroke care algorithms largely prioritize initial transport of stroke patients to the closest hospital equipped with the ability to administer IV-tPA. Therefore, the majority of patients only have access to EVT through inter-hospital transfers (drip and ship model), which are associated with significant treatment delays and worse outcomes, the paper said.

To study access, the researchers used 2017 claims data for Medicare and Medicaid to identify stroke centers that were EVT-capable. Of 1,941 stroke centers nationwide, 713 (37 percent) reported having done one or more EVTs for acute ischemic stroke. The researchers used geomapping techniques and 2010 census data to determine that 19.8 percent of the US population have direct access (within 15-minutes travel time) and 30.9 percent of the population could reach a center within 30 minutes.

Ready access to EVT varies greatly among states. Eight states have greater than 25 percent EVT coverage within 15 minutes, 34 states have 10 to 25 percent coverage, and nine states have less than 10 percent coverage, the study reported. Among the higher-access states were Arizona, California, Florida, Nevada, and North Dakota. Among the lower-access states were Alabama, Arkansas, Iowa, Mississippi, and New Hampshire.

The researchers then used mathematical models to ask the question of how EVT access could be improved. Would it be better to open more EVT centers, which they referred to as flipping? Or would it be better to make changes in emergency transportation systems to allow ambulances to bypass the closest non-EVT center to instead take patients who appear to have LVO to a center that offers EVT?

The researchers found that converting the top 10 percent of non-EVT centers to EVT centers would increase the direct coverage level from 19.8 percent to 27.1 percent. In comparison, using the bypass approach would increase access to EVT by 36.5 percent nationwide, with better or less results in some regions.

Overall, for the majority of states bypassing resulted in better coverage than flipping, the researchers concluded.

The study had several limitations, including the fact that the researchers used the criterion of one or more EVT claims to determine if a center was EVT-capable. The study did not consider volume of EVT procedures, outcomes, or costs of adding an EVT center at a hospital. They also did not consider the details of any given region or community, such as geography, traffic, availability of specialists who perform EVT, or the risk for stroke in the community. The makeup and size of a community's ambulance system could also influence whether the flipping or bypass model is better. The Mobile Stroke Unit in Houston, for example, is equipped to do CTs (which can detect LVO) and start tPA en route to the hospital.

One size by all means does not fit all, said Dr. Grotta. But he said every community should give thought to how to best improve access to EVT because this treatment (EVT) is extremely effective so there is an urgency to address this question.

David S. Liebeskind, MD, FAAN, professor of neurology at University of California Los Angeles and director of the UCLA Comprehensive Stroke Center, said that while the new study provided a useful theoretical look at how to improve access to EVT, any real-time local or state planning needs to engage all the stakeholders, including doctors, hospitals, community members, and public health officials. He said outcomes should be a key focus because there is a correlation between the number of EVTs done at a hospital and patient outcomes, with higher volume associated with better outcomes.

Everyone at the onset of stroke thinks the treatment should be straight forward and easy... that as long as you do your part (with EVT) the patient will do fine, said Dr. Liebeskind, president of the Society of Vascular and Interventional Neurology. But many stroke cases are complex and require expertise at all phases of care, not just in the endovascular suite.

Dr. Liebeskind said EVT centers tend to be financially desirable to hospitals, but he said market forces don't necessarily lead to an efficient distribution of resources or a system that gets the right patient to the right center at the right time.

He said there are more than 20 EVT centers in Los Angeles County, yet there are some pockets of the community that have limited access, whether due to geography or traffic congestion at peak times of day.

Dr. Liebeskind said that advances in telemedicineincluding the potential to perform EVT procedures remotelycould help improve access issues in rural or more remote communities.

Johanna T. Fifi, MD, FAAN, associate professor of neurology, neurosurgery and radiology and associate director of the Cerebrovascular Center at Mt. Sinai Hospital in New York City, said her hospital system has devised a model of care in which a team of EVT providers covers four different sites, including the main hospital and three others in its network.

Our team travels to the patient, she said. That model leads to our providers being very experienced. We do it (EVT) more often so our team is more experienced.

She said that the model also produces good outcomes by measure of the time it takes to get stroke patients into the procedure.

We find it's basically faster, than transferring the patient to the comprehensive stroke center, said Dr. Fifi, who added that a student researcher presented some of the results at the International Stroke Conference last month in Los Angeles.

Dr. Fifi said that while New York City overall has adopted a model of care that allows for ambulances to bypass a non-EVT center in favor of an EVT center based on a clinical assessment scale, she does not think that the bypass model favored in the new study is perfect.

No matter what, you are going to have some transfers of stroke patients from one center to another, Dr. Fifi said. You can't say you are going to do bypassing and expect no transfers.

M. Shazam Hussain, MD, director of the Cerebrovascular Center at the Cleveland Clinic, said that while it makes sense to say emergency responders should strive to identify patients who probably have LVO and could benefit if they are taken to an EVT center, what you really want to do is identify whether it's a severe stroke or a not a severe stroke. More severe strokes, regardless of the reason, need to be treated in larger, more equipped centers.

The Cleveland Clinic, a 12-hospital network, offers EVT at its main campus and three network hospitals, Dr. Hussain said, and some other hospitals in the area offer it as well.

Dr. Hussain said that a downside to adding more EVT centers to improve access in underserved areas is that you end up diluting the number of patients at each center, which could affect quality. But the bypass model, has some downsides as well, such as tying up emergency responders, and potentially delaying other critical treatments, such as thrombolysis, he said.

In organizing the ideal design and distribution of stroke care, so much comes down to regional and local factors, he said. Trying to mandate something so broadly across the country would be impossible.

Dr. Grotta receives consulting fees from Frazer Ltd., which manufactures mobile stroke units, and grant support from Genentech, which markets tPA. Dr. Liebeskind disclosed that he receives consulting fees from Imaging Core Lab for Cerenovus, Genentech, Medtronic, and Stryker. Dr. Fifi had no disclosures.

Original post:
Nearly 80 Percent of Americans Don't Have Timely Access to... : Neurology Today - LWW Journals

Oral Therapy Ozanimod Approved for Relapsing Forms of Multiple Sclerosis – Neurology Advisor

Posted on by

The Food and Drug Administration (FDA) has approved Zeposia (ozanimod; Bristol-Myers Squibb) for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.

Ozanimod, a sphingosine 1-phosphate (S1P) receptor modulator, binds with high affinity to S1P receptors 1 and 5 and blocks the capacity of lymphocytes to egress from lymph nodes, reducing the number of lymphocytes in peripheral blood.The mechanism by which it exerts therapeutic effects in MS is unknown but may involve the reduction of lymphocyte migration into the central nervous system.

The approval was based on data from 2 double-blind, parallel-group, active comparator-controlled clinical trials in patients with relapsing forms of MS. Both studies included patients who had experienced at least 1 relapse within the prior year, or 1 relapse within the prior 2 years with evidence of at least a gadolinium-enhancing (GdE) lesion in the prior year, and had an Expanded Disability Status Scale score from 0 to 5.0 at baseline.

Patients were randomized to receive ozanimod 0.92mg given orally once daily, beginning with a dose titration, or interferon beta-1a 30mcg given intramuscularly once weekly. The primary end point of both studies was annualized relapse rate (ARR) over the treatment period.

Results showed that in both trials, the ARR was statistically significantly lower in patients treated with ozanimod than in patients who received interferon beta-1a (Study 1: ARR 0.181 vs 0.350, respectively; Study 2: ARR 0.172 vs 0.276, respectively). Compared with interferon beta-1a, ozanimod demonstrated a relative reduction in ARR of 48% (P<.0001) through 1 year (Study 1) and 38% (P <.0001) at 2 years (Study 2). A similar effect was observed in exploratory subgroups defined by sex, age, prior nonsteroid therapy for MS, and baseline disease activity.

Moreover, the number of new or enlarging T2 hyperintense lesions and the number of GdE lesions were found to be statistically significantly lower in ozanimod-treated patients compared with patients who received interferon beta-1a.

With regard to safety, the most common adverse reactions associated with treatment included upper respiratory tract infection, hepatic transaminase elevation, orthostatic hypotension, urinary tract infection, back pain, and hypertension.

Ozanimod is contraindicated in patients who in the last 6 months, have experienced a myocardial infarction, unstable angina, stroke, transient ischemic attack, decompensated heart failure requiring hospitalization, or Class III or IV heart failure; have the presence of Mobitz type II second degree or third degree atrioventricular block, sick sinus syndrome, or sinoatrial block, unless the patient has a functioning pacemaker; have severe untreated sleep apnea; or are taking a monoamine oxidase inhibitor.

Before initiating therapy, a complete blood count (with lymphocyte count), an electrocardiogram, and liver function tests should be obtained; in patients with a history of uveitis or macular edema, an ophthalmic assessment is required.

Zeposia is supplied in 0.23mg, 0.46mg, 0.92mg strength capsules. According to BMS, commercialization will be delayed due to the COVID-19 pandemic.

For more information visit bms.com.

This article originally appeared on MPR

Read the original here:
Oral Therapy Ozanimod Approved for Relapsing Forms of Multiple Sclerosis - Neurology Advisor

Neurology congress goes virtual to give attendees access during COVID-19 pandemic – New Zealand Doctor Online

Posted on by

In the interests of the health, safety and wellbeing of all registered attendees and the wider public, the European Academy of Neurology (EAN) has cancelled all face-to-face activities and in-person attendance at its Annual Congress, scheduled to take place in Paris from May 23-26. Instead, attendees and speakers will have the opportunity to participate from home via the EAN Virtual Congress 2020, which will take place online. This decision has been taken due to the increasing public health burden throughout the world caused by the COVID-19 Coronavirus pandemic and to support public authorities globally in their effort to slow the spread of the disease.

The EAN Virtual Congress 2020 will allow attendees and speakers to participate from their computers without leaving their homes, no matter where they live. Difficult times ask for creative and courageous solutions which may also open new avenues for a better future. says Prof. Claudio Bassetti, Acting President of EAN, who goes on to explain that We must stay positive, strong and united more than ever to come through this crisis, which is why EAN, along with its partners, is playing its part in the fight against the pandemic by offering the online participation in the EAN Virtual Congress free-of-charge.

With conferences across many industries and fields already cancelled without online replacements, the EAN Virtual Congress is set to be one of the few meetings in neurology, as well as the biggest in 2020, as the conventional congress normally attracts more than 6,000 participants each year.

For those who have already registered for the EAN Paris 2020 Congress, fees will be refunded as soon as possible, and EAN is already contacting registered attendees. Registration for the EAN Virtual Congress will open on April 5, 2020 and will be available via the EAN website (www.ean.org).

About EAN

The European Academy of Neurology (EAN) is Europes home of neurology. Founded in 2014, through the merger of two European neurological societies, EAN represents the interests of more than 45,000 individual members and 47 national institutional members from across the continent. Each year, EAN brings together more than 6,000 neurologists and related scientists to the biggest general neurology conference in Europe. In addition to its overarching theme of Predict, Prevent, Repair, which are the three main challenges in dealing with neurological diseases, the EAN Virtual Congress 2020 will also cover all neurological diseases and disorders, including the big seven: epilepsy, stroke, headache, multiple sclerosis, dementia, movement disorders, neuromuscular disorders.

For further updates & information:For support regarding registrations & travel bookings for the Paris congress contact: registration@ean.org

For information related to the industry exhibition and sponsorship contact: industry@ean.org

For general information related to the EAN Virtual Congress see the FAQ page: https://www.ean.org/paris2020/FAQs.4318.0.html

Read more:
Neurology congress goes virtual to give attendees access during COVID-19 pandemic - New Zealand Doctor Online

Global Neurology Software Market 2020-2025: Increasing demand with Industry Professionals like Greenway Health, Kareo, Practice Fusion, Advanced Data…

Posted on by

The Global Neurology Software Market report draws precise insights by examining the latest and prospective industry trends and helping readers recognize the products and services that are boosting revenue growth and profitability. The study performs a detailed analysis of all the significant factors, including drivers, constraints, threats, challenges, prospects, and industry-specific trends, impacting the market on a global and regional scale. Additionally, the report cites worldwide market scenario along with competitive landscape of leading participants.

Get Sample Copy of the Report @ https://www.reportsweb.com/inquiry&RW00013259021/sample

The Neurology Software market analysis is intended to provide all participants and vendors with pertinent specifics about growth aspects, roadblocks, threats, and lucrative business opportunities that the market is anticipated to reveal in the coming years. This intelligence study also encompasses the revenue share, market size, market potential, and rate of consumption to draw insights pertaining to the rivalry to gain control of a large portion of the market share.

Leading Players in the Neurology Software Market: Epic, Bizmatics, Athenahealth, healthfusion, Allscripts, Nextgen, Brainlab, Greenway Health, Kareo, Practice Fusion, Advanced Data Systems, NueMD and more

Competitive landscape

The Neurology Software Industry is extremely competitive and consolidated because of the existence of several established companies that are adopting different marketing strategies to increase their market share. The vendors engaged in the sector are outlined based on their geographic reach, financial performance, strategic moves, and product portfolio. The vendors are gradually widening their strategic moves, along with customer interaction.

Neurology Software Market Segmented by Region/Country: US, Europe, China, Japan, Middle East & Africa, India, Central & South America

For discount click here: https://www.reportsweb.com/inquiry&RW00013259021/discount

Type of Neurology Software Market:

Advanced Neurology EMR Software

Other

Application of Neurology Software Market:

Hospitals

College & Research Institutes

Other

Points Covered in the Report:

Access full Report Description, TOC, Table of Figure, Chart, etc. @ https://www.reportsweb.com/buy&RW00013259021/buy/3660

Thanks for reading this article; you can also customize this report to get select chapters or region-wise coverage with regions such as Asia, North America, and Europe.

Table of Content

Chapter 1: Industry Overview

Chapter 2: Neurology Software Market International and China Market Analysis

Chapter 3: Environment Analysis of Market.

Chapter 4: Analysis of Revenue by Classifications

Chapter 5: Analysis of Revenue by Regions and Applications

Chapter 6: Analysis of Neurology Software Market Revenue Market Status.

Chapter 7: Analysis of Industry Key Manufacturers

Chapter 8: Conclusion of the Neurology Software Market Industry Research Report.

Continued to TOC

About ReportsWeb:

ReportsWeb is a one stop shop of market research reports and solutions to various companies across the world. We help our clients in their decision support system by assisting them choose most relevant and cost effective research reports and solutions from various publishers. We provide best in class customer service and our customer support team is always available to help you on your research queries.

Contact Us:

Name: Sameer JoshiEmail: sales@reportsweb.comPhone: +1-646-491-9876

See the article here:
Global Neurology Software Market 2020-2025: Increasing demand with Industry Professionals like Greenway Health, Kareo, Practice Fusion, Advanced Data...

Study Finds Picking up a Pingpong Paddle May Benefit People with Parkinson’s – Southernminn.com

Posted on by

MINNEAPOLIS, Feb. 26, 2020 /PRNewswire/ --Pingpong may hold promise as a possible form of physical therapy for Parkinson's disease. People with Parkinson's who participated in a pingpong exercise program once a week for six months showed improvement in their Parkinson's symptoms, according to a preliminary study released today that will be presented at the American Academy of Neurology's 72nd Annual Meeting in Toronto, Canada, April 25 to May 1, 2020.

Parkinson's disease is a movement disorder in which a chemical in the brain called dopamine is gradually reduced. This process results in slowly worsening symptoms that include tremor, stiff limbs, slowed movements, impaired posture, walking problems, poor balance and speech changes.

"Pingpong, which is also called table tennis, is a form of aerobic exercise that has been shown in the general population to improve hand-eye coordination, sharpen reflexes, and stimulate the brain," said study author Ken-ichi Inoue, M.D., of Fukuoka University in Fukuoka, Japan. "We wanted to examine if people with Parkinson's disease would see similar benefits that may in turn reduce some of their symptoms."

The study involved 12 people with an average age of 73 with mild to moderate Parkinson's disease. The people had been diagnosed with Parkinson's for an average of seven years.

The people were tested at the start of the study to see which symptoms they had and how severe the symptoms were.

Participants then played pingpong once a week for six months. During each weekly five-hour session, they performed stretching exercises followed by table tennis exercises with instruction from an experienced table tennis player. The program was developed specifically for Parkinson's disease patients by experienced table tennis players from the department of Sports Science of Fukuoka University.

Parkinson's symptoms were evaluated again after three months and at the end of the study.

The study found that at both three months and six months, study participants experienced significant improvements in speech, handwriting, getting dressed, getting out of bed and walking. For example, it took participants an average of more than two attempts to get out of bed at the beginning of the study compared to an average of one attempt at the end of the study.

Study participants also experienced significant improvements in facial expression, posture, rigidity, slowness of movement and hand tremors. For example, for neck muscle rigidity, researchers assessed symptoms and scored each participant on a scale of zero to four with a score of one representing minimal rigidity, two representing mild rigidity, three representing moderate rigidity and four representing severe rigidity. The average score for all participants at the start of the study was three compared to an average score of two at the end of the study.

Two participants experienced side effects. One person developed a backache and another person fell.

"While this study is small, the results are encouraging because they show pingpong, a relatively inexpensive form of therapy, may improve some symptoms of Parkinson's disease," said Inoue. "A much larger study is now being planned to confirm these findings."

The main limitation of the study was that the participants were not compared to a control group of people with Parkinson's disease who did not play pingpong. Another limitation was that a single specialist assessed the patients.

Learn more about Parkinson's disease at BrainandLife.org, home of the American Academy of Neurology's free patient and caregiver magazine focused on the intersection of neurologic disease and brain health. Follow Brain & Life on Facebook, Twitter and Instagram.

The American Academy of Neurology is the world's largest association of neurologists and neuroscience professionals, with more than 36,000 members. The AAN is dedicated to promoting the highest quality patient-centered neurologic care. A neurologist is a doctor with specialized training in diagnosing, treating and managing disorders of the brain and nervous system such as Alzheimer's disease, stroke, migraine, multiple sclerosis, concussion, Parkinson's disease and epilepsy.

For more information about the American Academy of Neurology, visit AAN.com or find us on Facebook, Twitter, Instagram, LinkedIn and YouTube.

Follow this link:
Study Finds Picking up a Pingpong Paddle May Benefit People with Parkinson's - Southernminn.com

A smart jumpsuit that accurately measures the infants movement and development – Tech Explorist

Posted on by

Infants spontaneous and voluntary movements mirror the developmental integrity of brain networks since they require coordinated activation of multiple sites in the central nervous system. Accordingly, early detection of infants with atypical motor development holds promise for recognizing those infants who are at risk for a wide range of neurodevelopmental disorders.

Previously, novel wearable technology has shown promise for offering efficient, scalable, and automated methods for movement assessment in adults. Now, scientists from the University of Helsinki have developed a smart jumpsuit or a garment that accurately measures the spontaneous and voluntary movement of infants from the age of five months.

Sampsa Vanhatalo, professor of clinical neurophysiology at the University of Helsinki, said, The smart jumpsuit provides us with the first opportunity to quantify infants spontaneous and voluntary movements outside the laboratory. The child can be sent back home with the suit for the rest of the day. The next day, it will be returned to the hospital, where the results will then be processed.

The new analysis method quantifies infant motility as reliably as a human being would be able to do by viewing a video recording. After the measurement, the infants actual movements and physical positions will be known to the second, after which computational measures can be applied to the data.

This is a revolutionary step forward. The measurements provide a tool to detect the precise variation in motility from the age of five months, something which smart medical clothes have not been able to do until now.

The jumpsuit can detect abnormalities in the neurological development of infants at an early stage. Hence, it enables new support.

According to Leena Haataja, professor of pediatric neurology, developmental disorders in todays pressure-dominated world pose a considerable risk that can lead to learning difficulties and obstacles in the competition for education and jobs. Furthermore, they are a risk factor associated with exclusion from contemporary society.

Haataja said, The early identification of developmental disorders and support for infants everyday functional capacity in interaction with the family and the growth environment constitute a significant factor on the level of individuals, families, and society.

Haataja noted, The early identification of developmental disorders and support for infants everyday functional capacity in interaction with the family and the growth environment constitute a significant factor on the level of individuals, families, and society.

Smart jumpsuit can be used for the objective measurement of how various therapies and treatments affect childrens development.

The study is published in the Scientific Reports journal.

Read more here:
A smart jumpsuit that accurately measures the infants movement and development - Tech Explorist

Global Neurology Software Market Drivers, Key Players, Regions, Application and Forecast to 2020-2025 – Nyse Nasdaq Live

Posted on by

This study has articulated the Global Neurology Software Market with a detailed view of the Global Neurology Software industry including Global production sales, Global revenue, and CAGR. The report delivers core insights regarding the Neurology Software Market report with an in-depth study of market size, country-level market size, region, segmentation market growth, market share, sales analysis, value chain optimization, market players, the competitive landscape, recent developments, product launches, strategic market growth analysis, trade regulations, opportunities analysis, technological innovations, and area marketplace expanding. Moreover, it critically focuses on the application by analyzing the growth rate and consumption of every individual application.

Key vendor/manufacturers in the market:

The major players covered in Neurology Software are: Epic, Brainlab, healthfusion, Athenahealth, Practice Fusion, Nextgen, Bizmatics, Greenway Health, Allscripts, Kareo, Advanced Data Systems, NueMD, etc.

Request a sample of this report @ https://www.orbisresearch.com/contacts/request-sample/4162760

The Neurology Software Market report majorly offers an understanding about the major drivers, challenges, restraints, competitive landscape, increasing trends, market dynamics, market size, and market share, development status along with government policy, investment opportunities, and supply chains. It categorizes and analyze the segments regarding type, region, and application. This research report offers an aerial view of the Global Neurology Software Market including market share, price, revenue, growth rate, production by type.

The Global Neurology Software Market landscape and leading manufacturers offers competitive landscape and market development status including the overview of every individual market players. Furthermore, it offers productive data of vendors including the profile, specifications of product, applications, annual performance in the industry, sales, revenue, investments, acquisitions and mergers, market size, market share, and more.

The report also understand the export and import, production, and consumption of every particular region holding highest market share, market size, or CAGR. Furthermore, it provides a an potential insights regarding Porters Five Forces including substitutes, potential entrants, buyers, industry competitors, and suppliers with genuine information for understanding the Global Neurology Software Market.

Browse the complete report @ https://www.orbisresearch.com/reports/index/global-neurology-software-market-2020-by-company-regions-type-and-application-forecast-to-2025

Global Neurology Software Market By Type:

By Type, Neurology Software market has been segmented into Advanced Neurology EMR Software, Other, etc.

Global Neurology Software Market By Application:

By Application, Neurology Software has been segmented into Hospitals, College & Research Institutes, Other, etc.

Report covers detailed study about the gross margin, production, revenue, the price of the Global Neurology Software Market regarding different regions covered in particular section. It majorly focuses on manufacturing analysis including about the raw materials, cost structure, process, operations, and manufacturing cost strategies. The report introduces the industrial chain analysis, downstream buyers, and raw material sources along with the accurate insights of market dynamics. The Neurology Software Market reports delivers the knowledge about market competition between vendors through regional segmentation of markets in terms of revenue generation potential, business opportunities, demand & supply.

The report concludes with the coverage of data of big companies with information about their sales data, upcoming innovations and development, revenue margins, investments, business models, strategies, and business estimations.

Make an enquiry of this report @ https://www.orbisresearch.com/contacts/enquiry-before-buying/4162760

Major Table of Contents

1 Neurology Software Market Overview2 Company Profiles3 Market Competition, by Players4 Market Size by Regions5 North America Neurology Software Revenue by CountriesContinued

About Us:

Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customized reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialization. This helps our clients to map their needs and we produce the perfect required market research study for our clients.

Contact Us: Hector CostelloSenior Manager Client Engagements4144N Central Expressway,Suite 600, Dallas,Texas 75204, U.S.A.Phone No.: USA: +1 (972)-362-8199 | IND: +91 895 659 5155Email ID: [emailprotected]

Read the original here:
Global Neurology Software Market Drivers, Key Players, Regions, Application and Forecast to 2020-2025 - Nyse Nasdaq Live

The One Food A Neurologist Wants You To Eat (That You May Not Know) – mindbodygreen.com

Posted on by

When it comes to eating healthy, we're always on the hunt for lesser-known powerhouse veggies to incorporate into our diets. We asked neurologist and mbg Collective member David Perlmutter, M.D., what food he wants us all to eat in 2020, and he answered with a resounding (and fairly surprising) vegetable.

"We've known for a long time that broccoli is good food for us," Perlmutter said in an Instagram post. "It helps out the body's antioxidant function; it helps us reduce inflammation; it helps with detoxification."

But he's not pushing regular old broccoli. Rather, Perlmutter wants us to be eating broccoli sprouts.

Broccoli sprouts, at their most basic, are just what they sound like: an immature version of the cruciferous vegetable we all know and love. What makes them different and packs their power is a higher concentration of the necessary components to boost the production of sulforaphane.

In studies, sulforaphane has been linked to fighting against certain carcinogens, and it may support heart health and brain recovery as well. Researchers have also found it can support gut health, rounding out a pretty solid set of benefits that you may be able to attribute to these little sprouts.

Read the original:
The One Food A Neurologist Wants You To Eat (That You May Not Know) - mindbodygreen.com

LDL and Stroke Prevention: How Low to Go – Medscape

Posted on by

This transcript has been edited for clarity.

Dear colleagues, I'm Christoph Diener, a neurologist from the University of Duisburg-Essen in Germany, here to discuss five interesting studies published in November 2019.

There are a number of registry studies indicating that low vitamin D3 levels are, perhaps, a risk factor in multiple sclerosis. In a publication in Neurology, investigators behind the SOLAR study reported results in 229 patients with relapsing-remitting multiple sclerosis treated with interferon-beta-1a. Patients were then randomized to receive either 14,000 units of vitamin D3 per day or placebo.

The primary endpointno evidence of disease activity at week 48was achieved by 35% in both treatment groups. Although there was no benefit to vitamin D3 overall, a subgroup analysis did show a tendency toward fewer new lesions on MRI imaging with vitamin D3.

A study published in The New England Journal of Medicine addressed the very important question of what is the best treatment for patients with status epilepticus who initially do not respond to benzodiazepines. Investigators randomized patients to receive levetiracetam (145 patients), fosphenytoin (118), or valproate (121).

The primary endpoint of absence of clinically evident seizures and improvement in the level of consciousness by 60 minutes after the start of drug infusion was achieved in 45%-47% of patients across the three treatments. There was no difference in efficacy. In terms of adverse events, there was a higher, but statistically insignificant, number of patients with hypotension and need for intubation in the fosphenytoin group, and a slightly higher mortality in the levetiracetam group.

Also published in The New England Journal of Medicine were results from the Treat Stroke to Target study. Investigators addressed the question of how low should the LDL cholesterol be in secondary stroke prevention after ischemic stroke or transient ischemic attack. They recruited 2860 patients and randomized them to two target groups: an LDL of < 70 mg/dL or an LDL between 90 and 110 mg/dL. Patients were followed for a median of 3.5 years.

The primary endpoint of major cardiovascular events or deaths from cardiovascular causes was reached in 8.5% in the lower-target group, who achieved an LDL of 65 mg/dL, and in 10.9% in the higher-target group, who achieved an LDL of 96 mg/dL. This translates to a hazard ratio of 0.78, representing a significant 22% risk reduction (P = .04).

The ACHIEVE II Study investigated the oral calcitonin gene-related peptide receptor antagonist ubrogepant versus placebo for the treatment of acute migraine attacks. Investigators recruited 1686 patients (90% female) who received ubrogepant at 25 or 50 mg or placebo.

The primary endpoint of being pain-free 2 hours after taking the medication was achieved by approximately 21% of the patients receiving ubrogepant at either dose, compared with 14% of the placebo group. There were very few side effects with ubrogepant outside of a little bit of nausea and dizziness.

However, this study was unable to answer the most important question of whether this new drug is equivalent in efficacy to sumatriptan. The other important question is whether this drug can be used in people who have contraindications for triptans, which, unfortunately, this study also could not answer.

Published in The Lancet, the CRASH-3 study investigated the possible benefit of tranexamic acid in acute brain injury with intracranial bleeding. Tranexamic acid, unfortunately, was not effective in spontaneous intracerebral haemorrhage. The current study recruited more than 12,000 patients who were randomized to receive tranexamic acid or placebo within 3 hours of brain injury. Participants had to have a Glasgow Coma Scale score of 12 or less and an intracranial bleed.

The death rate was 18.5% for tranexamic acid versus 19.8% for placebo, which translates to a 6% risk reduction that almost reached statistical significance. There was a statistically significant benefit if patients with very severe head injury were excluded. Here the risk reduction was 11% and was significant.

Tranexamic acid is obviously an option for people with traumatic intracranial haemorrhage. It's cheap, it's safe, and it did not lead to an increased risk for vascular occlusive disease.

Ladies and gentlemen, I'm Christoph Diener from the University of Duisburg-Essen. Thank you very much for listening about these five interesting studies from November 2019.

Dr Diener is an expert in the treatment of stroke and headache, and chairs the German Headache Consortium and the German Stroke Data Bank.

Follow Medscape on Facebook, Twitter, Instagram, and YouTube

Read more:
LDL and Stroke Prevention: How Low to Go - Medscape

The Lancet Neurology: Discovery could speed diagnosis and treatment of children with life-threatening neurological diseases – Science Codex

Posted on by

In the study, 85% (99/116) of children with life-threatening autoimmune conditions had complete or near complete recovery after biomarker was spotted and they were subsequently given appropriate treatment

A group of life-threatening neurological conditions affecting children have been linked to an antibody which points to potential treatment, according to an observational multicentre study involving 535 children with central nervous system (CNS) demyelinating disorders and encephalitis, published in The Lancet Neurology journal.

The findings suggest that the myelin oligodendrocyte glycoprotein (MOG) antibody is associated with a wider range of life-threatening autoimmune conditions than previously thought, including neuromyelitis optica spectrum disorders and encephalitis, which cause severe neurological (brain and nervous system) symptoms such as vision loss, muscle weakness, and loss of coordination and speech.

Because this group of CNS disorders can mimic similar conditions like multiple sclerosis (MS), they are difficult to diagnose correctly. Until around 10 years ago, patients with these demyelinating diseases were considered to have atypical forms of MS, and the prognosis and best treatment options were unknown. Over the last 10 years, multiple studies have shown that several demyelinating diseases (including optic neuritis, myelitis, and acute disseminated encephalomyelitis [ADEM]) associate with the MOG-antibody biomarker, and patients affected by this group of diseases frequently improve with immunotherapy. However, the best treatment approach and long-term outcome remain unknown. Now, this new study suggests that testing for the biomarker could speed accurate diagnosis and help identify the appropriate treatment for some of these disorders.

In the study, 85% (99/116) children who tested positive for MOG antibodies and given appropriate treatment had complete or near complete recovery, but 15% (17) experienced moderate to severe disease-related deficits not caused by the treatment (eg, cognitive impairment, epilepsy, vision loss), and one died from their disease.

"The diagnosis of many of these patients especially those with encephalitis would have been missed if it were not for the prospective design our study," says Dr Thais Armangue from the Sant Joan de Deu Children's Hospital, University of Barcelona, in Spain who co-led the research. "Identifying these patients is important because most of the children who tested positive for MOG antibodies responded to treatment with immunotherapy." [1]

Co-lead author Professor Josep Dalmau from the University of Barcelona explains, "Demyelinating diseases in children can be very difficult to distinguish because they present with similar symptoms and imaging features. Correct and early diagnosis allows for treatment with immunosuppressants, rather than the treatments specifically used in MS that are not effective in most of these diseases. Moreover, it is important to differentiate between those diseases that do not require chronic treatment and others in which prolonged immunotherapy is needed to improve long-term outcomes." [1]

MOG antibodies damage the protective covering (myelin sheath) that surrounds nerve fibres in the brain, optic nerves, and spinal cord, so messages cannot pass along these nerves effectively, causing symptoms such as vision loss, muscle weakness, and pain. Many children may only experience one MOG antibody disease event, and have no further symptoms. However, some children may be at risk of further relapses months, sometimes years, later.

Although there is increasing recognition of MOG-antibody associated syndromes in children, the full range of diseases associated with MOG antibodies remains unknown.

To provide more evidence, researchers conducted a prospective study of children (median age 6 years) with suspected demyelinating syndromes (239 children) and encephalitis other than ADEM (296) attending 40 hospitals across Spain between June 1, 2013, and December 31, 2018. Participants who tested positive for MOG antibodies were assessed for clinical features, response to treatment (ie, number of relapses), and outcomes over a median follow-up of 42 months.

In total, 116 (22%) of 535 children were found to be positive for MOG antibodies, including 94 (39%) with demyelinating syndromes and 22 (7%) with autoimmune encephalitis. Importantly, 24% (28/116) of these children had syndromes not previously associated with MOG antibodies.

Among the 64 patients with autoimmune encephalitis, MOG antibodies were the most frequent biomarkers--more common than all other neuronal antibodies combined (22 [34%] vs 21 [33%])--suggesting that MOG antibody testing should be conducted when diagnosing children with suspected encephalitis after excluding infectious causes, particularly as these patients often respond to treatment with immunotherapy.

The findings also suggest that younger children with MOG-antibody associated syndromes tend to present with clinical features of ADEM (which is an inflammatory condition that mainly affects the brain), whilst older children are more likely to have signs of optic neuritis (eg, loss of vision, pain in the eye) or myelitis (eg, back pain, weakness in both legs).

During follow-up, 33 (28%) of 116 patients positive for MOG antibody disease had relapses. Most of these patients (99/116, 85%) recovered well. However, 17 (15%) experienced disease-related moderate to severe deficits, and one died due to their disease.

"Despite advances in diagnostic testing for encephalitis, up to half of cases have no clear cause. Our findings reveal that the spectrum of MOG antibody disease is broader than previously thought and includes autoimmune encephalitis as well as multiple demyelinating syndromes", says co-author Dr Gemma Olive-Cirera from the Sant Joan de Deu Children's Hospital, University of Barcelona, Spain. "In light of our findings, current classifications and terminology of MOG antibody-associated syndromes should be updated." [1]

The authors note several limitations, including that this was not a registry-based study, and therefore could not assess the incidence or prevalence of MOG antibody-associated syndromes, and that the follow-up was short, which could result in the frequency of relapses being underestimated.

Writing in a linked Comment, Dr Romain Marignier from the Hpital Neurologique Pierre Wertheimer, France (who was not involved in the study) describes the research as "a milestone in the understanding of MOG antibody-associated syndromes", and writes: "In view of the very broad clinical spectrum now associated with MOG autoimmunity, the next challenge will be to identify the optimal therapeutic strategy for each clinical presentation. This objective is closely connected to a better understanding of the pathogenic role of MOG antibodies, and the need for early, robust, and specific prognostic factors of relapse and disability."

Go here to read the rest:
The Lancet Neurology: Discovery could speed diagnosis and treatment of children with life-threatening neurological diseases - Science Codex

NeurologyLive Adds the Consortium of Multiple Sclerosis Centers to Its Strategic Alliance Partnership Program – Business Wire

Posted on by

CRANBURY, N.J.--(BUSINESS WIRE)--NeurologyLive, a multimedia platform dedicated to providing health care professionals treating neurological diseases with direct access to expert-driven, practice-changing news and insights in neurology, announces the addition of the Consortium of Multiple Sclerosis Centers (CMSC) to its Strategic Alliance Partnership (SAP) program.

We are proud to be working with the CMSC, said Mike Hennessy Jr., president and CEO of MJH Life Sciences, parent company of NeurologyLive. CMSC works to improve the lives of all who have been affected by MS by bringing together a society of MS medical professionals.

CMSC is an organization of multiple sclerosis health care professionals who strive to improve the lives of those affected by multiple sclerosis (MS). With over 250 member centers in the United States and Canada, CMSC represents over 12,000 health care professionals worldwide who provide care for more than 500,000 individuals with MS and their families.

NeurologyLive embraces a model of education and outreach that is consistent with the mission of the CMSC: a team approach, said June Halper, MSN, APN-C, CEO of CMSC. The target audience includes a constellation of professionals and supportive organizations allowing the CMSCs message to be heard loud and clear. We are grateful for this partnership.

The NeurologyLive SAP program is constantly building a community of health plans, advocacy groups, medical associations and medical institutions to foster collaboration and an open exchange of information for the ultimate benefit of patients and their families and to improve patient care. As part of this joint effort, NeurologyLive and CMSC will share exclusive content with each other.

For more information about the NeurologyLive SAP program, click here. For more information about CMSC, click here.

About NeurologyLive

A multimedia platform for health care professionals treating neurological diseases, NeurologyLive delivers direct access to practice-changing news and expert insights directly from top medical conferences and researchers to improve the lives of patients with neurological diseases such as dementia and Alzheimer disease, epilepsy, headache and migraine, movement disorders, multiple sclerosis, neuromuscular diseases, sleep disorders and stroke. The NeurologyLive platform offers an in-depth look at the hundreds of new treatments in development with ever-expanding mechanisms of action, all during an unprecedented time of growing demand for neurology expertise. The NeurologyLive platform also connects visitors with the most up-to-date clinical trial results, Food and Drug Administration approvals, practice-changing research and expert insights. NeurologyLive is a brand of MJH Life Sciences, the largest privately held, independent, full-service medical media company in North America dedicated to delivering trusted health care news across multiple channels.

About Consortium of Multiple Sclerosis Centers (CMSC)

The Consortium of Multiple Sclerosis Centers (CMSC), is the leading educational, training, and networking organization for MS healthcare professionals, researchers and professionals in training. The CMSC mission is to promote high quality MS care through educational programming and accreditation including live and online events, research grants, technical journals and papers, and targeted advocacy efforts. The CMSC member network includes more than 12,000 international healthcare clinicians and scientists committed to MS care as well as more than 60 Veterans Administration MS Programs and 250 MS Centers in the US, Canada, and Europe. The 34th CMSC Annual Meeting, the largest gathering of MS healthcare professionals in North America, will take place May 27 30, 2020, in Orlando, FL. For more information visit: http://www.mscare.org. Follow CMSC on Twitter: @mscare and Facebook: http://www.facebook.com/CMSCmscare.

Read more:
NeurologyLive Adds the Consortium of Multiple Sclerosis Centers to Its Strategic Alliance Partnership Program - Business Wire